E Fund Management Co., Ltd. Arrowhead Pharmaceuticals, Inc. Transaction History

E Fund Management Co., Ltd.

$1.93 Billion
Q3 2024

A detailed history of E Fund Management Co., Ltd. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 11,438 shares of ARWR stock, worth $216,864. This represents 0.01% of its overall portfolio holdings.

Number of Shares

11,438

Previous 8,900 28.52%

Holding current value

$216,864

Previous $231,000 4.33%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$19.36 - $29.54 $49,135 - $74,972	2,538 Added 28.52%	11,438 $221,000
Q2 2024 Aug 12, 2024	SELL	$21.87 - $28.24 $88,704 - $114,541	-4,056 Reduced 31.31%	8,900 $231,000
Q1 2024 May 13, 2024	SELL	$27.21 - $39.48 $178,905 - $259,580	-6,575 Reduced 33.66%	12,956 $370,000
Q4 2023 Feb 06, 2024	BUY	$21.2 - $31.03 $89,845 - $131,505	4,238 Added 27.71%	19,531 $597,000
Q3 2023 Nov 13, 2023	BUY	$26.2 - $36.08 $69,351 - $95,503	2,647 Added 20.93%	15,293 $411,000
Q2 2023 Aug 11, 2023	SELL	$25.16 - $41.38 $51,150 - $84,125	-2,033 Reduced 13.85%	12,646 $451,000
Q1 2023 May 11, 2023	BUY	$23.68 - $38.51 $16,599 - $26,995	701 Added 5.02%	14,679 $373,000
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $45,556 - $65,991	1,627 Added 13.17%	13,978 $567,000
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $59,141 - $96,426	-1,996 Reduced 13.91%	12,351 $408,000
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $220,263 - $401,134	7,926 Added 123.44%	14,347 $505,000
Q1 2022 May 12, 2022	BUY	$39.62 - $69.97 $178,884 - $315,914	4,515 Added 236.88%	6,421 $295,000
Q1 2021 May 12, 2021	BUY	$61.35 - $90.47 $116,933 - $172,435	1,906 New	1,906 $126,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.01B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.

Account

E Fund Management Co., Ltd. Arrowhead Pharmaceuticals, Inc. Transaction History